EP300 and cancer: Inhibition of CBP/p300 has been shown to reduce H3K27ac, downregulate oncogene transcription, induce cancer cell growth inhibition and cell death, activate immune response, overcome drug resistance, suppress tumor progression in vivo, and enhance the anticancer efficacy of radiotherapy [107].